Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia

Clinical and Experimental Immunology

Volumn 188, Issue 2, 2017, Pages 275-282

  Audia, S ^a,b,d   Santegoets, K ^d   Laarhoven, A G ^e   Vidarsson, G ^e   Facy, O ^c   Ortega Deballon, P ^c   Samson, M ^a,b   Janikashvili, N ^a   Saas, P ^a   Bonnotte, B ^a,b   Radstake, T R ^d  

^a UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^b Department of Internal Medicine and Clinical Immunology   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e SANQUIN RESEARCH   (Netherlands)

Author keywords

autoimmunity; Fc receptors; macrophages; spleen

Indexed keywords

CD86 ANTIGEN; FC RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; CD86 PROTEIN, HUMAN; FCGR3A PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MACROPHAGE; MACROPHAGE FUNCTION; MALE; MIDDLE AGED; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN; SPLEEN FUNCTION; SPLENECTOMY; SPLENIC MACROPHAGE; TREATMENT DURATION; AGED; AUTOIMMUNE DISEASES; BLOOD; CYTOLOGY; GENETICS; IMMUNOLOGY; PHENOTYPE; PHYSIOLOGY; THROMBOCYTOPENIA;

ADULT; AGED; ANTIGENS, CD86; AUTOIMMUNE DISEASES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MACROPHAGES; MALE; MIDDLE AGED; PHAGOCYTOSIS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, IGG; SPLEEN; SPLENECTOMY; THROMBOCYTOPENIA;

EID: 85014266871     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12935     Document Type: Article

References (38)

1. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010; 236:265–75.
2. Niederer HA, Clatworthy MR, Willcocks LC, Smith KG. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann NY Acad Sci 2010; 1183:69–88.
3. Radstake TR, Blom AB, Sloetjes AW et al. Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis. Ann Rheum Dis 2004; 63:1556–63.
4. Wenink MH, Santegoets KC, Roelofs MF et al. The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease. J Immunol 2009; 183:4509–20.
5. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005; 307:590–3.
6. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99:4–13.
7. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994; 83:1024–32.
8. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982; 59:23–6.
9. Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost 2009; 7:322–9.
10. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013; 13:176–89.
11. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981; 36:81–6.
12. Imbach P, Barandun S, Hirt A, Wagner HP. Intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP) in childhood. Am J Pediatr Hematol Oncol 1984; 6:171–4.
13. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113:3154–60.
14. Nagelkerke SQ, Dekkers G, Kustiawan I et al. Inhibition of FcgammaR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcgammaRIIb in human macrophages. Blood 2014; 124:3709–18.
15. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670–3.
16. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484–6.
17. Carcao MD, Blanchette VS, Wakefield CD et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 2003; 120:135–41.
18. Amorim DM, Silveira Vda S, Scrideli CA, Queiroz RG, Tone LG. Fcgamma receptor gene polymorphisms in childhood immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2012; 34:349–52.
19. Foster CB, Zhu S, Erichsen HC et al. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 2001; 113:596–9.
20. Papagianni A, Economou M, Tragiannidis A et al. FcgammaRIIa and FcgammaRIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome. Blood Coagul Fibrinolysis 2013; 24:35–9.
21. Breunis WB, van Mirre E, Bruin M et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008; 111:1029–38.
22. Bruin M, Bierings M, Uiterwaal C et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br J Haematol 2004; 127:561–7.
23. Najean Y, Rain JD, Billotey C. The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol 1997; 97:547–50.
24. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190–207.
25. Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168–86.
26. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005; 90:829–32.
27. Audia S, Samson M, Guy J et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011; 118:4394–400.
28. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115:2914–23.
29. Veri MC, Gorlatov S, Li H et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 2007; 121:392–404.
30. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol 2012; 188:1318–24.
31. Liu XG, Ma SH, Sun JZ et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood 2011; 117:2061–9.
32. Crow AR, Song S, Freedman J et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003; 102:558–60.
33. Leontyev D, Katsman Y, Branch DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood 2012; 119:5261–4.
34. Wu Z, Zhou J, Prsoon P, Wei X, Liu X, Peng B. Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals. Int J Hematol 2012; 96:588–93.
35. Shimomura M, Hasegawa S, Seki Y, Fukano R, Hotta N, Ichiyama T. Intravenous immunoglobulin does not increase FcgammaRIIB expression levels on monocytes in children with immune thrombocytopenia. Clin Exp Immunol 2012; 169:33–7.
36. Liu XG, Liu S, Feng Q et al. Thrombopoietin receptor agonists shift the balance of Fcgamma receptors toward inhibitory receptor IIb on monocytes in ITP. Blood 2016; 128:852–61.
37. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109–14.
38. Catani L, Fagioli ME, Tazzari PL et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006; 34:879–87.